Embody vs Wisp
An in-depth comparison of two leading GLP-1 Providers
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
Embody
Best for lowest first-month entry pricing on compounded GLP-1sStarting at $99/mo
Wisp
Best for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-testedStarting at $225/mo
Side-by-Side Comparison
| Feature | Embody | Wisp |
|---|---|---|
| Overall Score | ✓8.5/10 | 7.0/10 |
| Starting Price | ✓$99/mo | $225/mo |
| Editorial Rating | ✓4.3 ★ /5 | 3.5 ★ /5 |
| Features | 6 features | 6 features |
| States Available | 0 | 0 |
| Compounded | ✓ Yes | ✓ Yes |
| Brand Name | — | — |
| FSA/HSA Accepted | — | — |
| FDA Warnings | None | None |
Pros & Cons
Embody
Pros
- ✓Lowest first-month entry pricing in the compounded segment ($99 first month for semaglutide, $149 for tirzepatide injection)
- ✓Unique compounded oral tirzepatide gum formulation — alternative for patients who prefer not to inject
- ✓Available in all 50 states with no insurance friction
- ✓24/7 unlimited clinician messaging and dose-adjustment support included
- ✓Medical leadership by Dr. Alan Viglione, board-certified in Internal Medicine
Cons
- ✗Refill pricing jumps to $299/month after the first month — initial $99/$149 is an intro rate, not the ongoing cost
- ✗Compounded only — no FDA-approved brand-name Ozempic, Wegovy, Zepbound, or Mounjaro option
- ✗Pharmacy partners not publicly named — compounding source transparency is limited
- ✗Compounded oral tirzepatide does not have an FDA-approved counterpart, and oral GLP-1 bioavailability remains an active area of clinical debate
Wisp
Pros
- ✓Wider GLP-1 menu than the prior stub suggested — both branded injectables (Wegovy, Zepbound, Saxenda) AND the compounded sublingual option
- ✓LegitScript certified, board-certified providers (Dr. Shannon Chatham DO, Andrea Sleeth WHNP-BC publicly named)
- ✓Wisp's product page uses appropriately cautious language around sublingual: 'lab tests using human-derived tissues suggest it may begin working' and 'effectiveness in patients may vary' — disclosure is more rigorous than most compounded GLP-1 marketing
Cons
- ✗EFFECTIVENESS CAVEAT: sublingual compounded semaglutide has not been tested in humans — Wisp's own product page explicitly states this. Injectables (Wegovy, Zepbound, Saxenda) on the same platform have FDA safety/efficacy data; sublingual does not.
- ✗Pharmacy partners not publicly named
- ✗States served list not publicly enumerated
Our Verdict
Embody edges out Wisp with a higher overall score of 8.5/10 and is particularly strong for lowest first-month entry pricing on compounded GLP-1s. Wisp remains a solid alternative, especially if you're looking for buyers who want a board-certified telehealth platform offering both branded injectables AND a sublingual alternative — with full disclosure that the sublingual form is not human-tested.
Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.